Five-fraction HDR brachytherapy in locally advanced cervical cancer: A monocentric experience

Ogorodniitchouk, Oleksandr; Aunier, J.; Bousarsar, Amal; Lahmamssi, C.; Sotton, Sandrine; Ouaz, Hamza; Moreno‐Acosta, Pablo; Moslemi, Dariush; Molekzadehmoghani, M.; Langrand-Escure, Julien; Magné, Nicolas; Vallard, Alexis

doi:10.1016/j.canrad.2021.03.006

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the last decades, the development of IGABT provided clinical evidence of improved clinical outcomes of modern brachytherapy in cervical cancer [2,15,[27][28][29][30][31][32]. The use of MRI plays an important role in the accurate delineation of tumor and critical organs, allowing dose escalation to clinical target volumes (CTVs) [20][21][22][23]. In small tumors and those with a favorable response to chemoradiotherapy, intra-cavitary brachytherapy is an adequate and effective modality of brachytherapy [2].…”

Section: Discussionmentioning

confidence: 99%

“…Depending on the tumor response at the end of CCRT, two BT schedules were applied. For good responders or low-risk tumors, BT was performed with one implant and delivered in 2 fractions per day (6 h apart) during three consecutive days, with prescribed dose of 27.5 Gy in 5 fractions of 5.5 Gy at D 90 HR-CTV [ 22 ]. For high-risk or poorly responders’ tumors requiring combined intra-cavitary and interstitial (or treatment adaptation due to insufficient target volume coverage during first implant), four fractions in two implants (two fractions each one) of HDR brachytherapy were delivered about 1 week apart (fraction 1, 2 and 3, 4).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario

Cagetti¹,

Zemmour²,

Lambaudie³

et al. 2022

jcb

View full text Add to dashboard Cite

Purpose: To investigate the feasibility and early clinical outcomes of combined intra-cavitary (IC) and interstitial (IS) image-guided adaptive brachytherapy (IGABT) as curative and definitive treatment of patients treated with chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC).Material and methods: Data from medical records of all consecutive patients with histologically proven cervical cancer (FIGO 2018 stage IB-IV), treated by brachytherapy after CCRT at our institution between 2017 and 2020 were reviewed.Results: One hundred and forty-two patients with LACC FIGO 2018 stages (IB: 20.4%, II: 31.7%, III: 45.8%, IV: 2.1%) underwent brachytherapy at our institution, out of which 53.5% underwent combined brachytherapy technique (IC/IS). Median number of implanted catheters was 3 (range, 1-6 catheters). None of the 142 patients required invasive hemorrhage management. With a median follow-up of 21.6 (95% CI [confidence interval]: 19.1-23.5%) months, local relapse was observed in nine patients (6.3%), with four showing persistent and progressive disease. The estimated 2-year local and pelvic relapse-free survival were 92% (95% CI: 84-96%) and 90% (95% CI: 83-94%), respectively. The estimated 2-year disease-free survival for the entire population was 80% (95% CI: 71-87%). The 2-year overall survival (OS) rate for the entire population was 92% (95% CI: 84-96%). Acute toxicity G3 was reported in two (1.4%) patients. High-grade late toxicity (grade 3) was reported in 9 (6.3%) patients.Conclusions: Combined IC/IS brachytherapy for LACC allows for recommended doses to achieve local control even in large tumors after CCRT improving target volume coverage, with low rates of acute morbidity. Hybrid brachytherapy technique (IC/IS) is essential to have a favorable scenario at the time of brachytherapy to correctly treat locally advanced cervical cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario

Cagetti¹,

Zemmour²,

Lambaudie³

et al. 2022

jcb

View full text Add to dashboard Cite

show abstract

“…No período deste estudo (2018 e 2019), no estado de Santa Catarina, somente o CEPON ofertava sedação às mulheres durante a braquiterapia de alta taxa de dose, limitando esse serviço às mulheres não histerectomizadas. Neste grupo de pacientes, os aplicadores são introduzidos até o útero (7) .…”

unclassified

Avaliação Da Dor Em Mulheres Com Câncer Cérvico-Uterino Durante a Braquiterapia

Rosa

Lunardi²,

Hames³

et al. 2022

Cogit. Enferm.

View full text Add to dashboard Cite

Objetivo: avaliar a intensidade da dor em mulheres submetidas à braquiterapia pélvica. Método: estudo transversal, analítico, quantitativo realizado em instituição oncológica (Santa Catarina/Brasil), incluindo 97 mulheres em braquiterapia pélvica, com (grupo 1) ou sem (grupo 2) sedação anestésica. Coleta de dados entre setembro de 2018 a julho de 2019, por entrevista estruturada e no prontuário da paciente. Intensidade da dor avaliada em cinco momentos por escala visual analógica. Análise incluiu medidas de frequência, teste qui-quadrado, análise de resíduos padronizados ajustados, equações de estimações generalizadas, teste post-hoc de Bonferroni; nível de significância 0,05. Resultados: 51 mulheres (52,6%) referiram dor prévia à braquiterapia, 73 (75,3%) após. Na retirada dos aplicadores, grupo 1 atingiu 55,9% na proporção de presença de dor, grupo 2 36,8%. Houve significância da percepção dolorosa por momento/sedação (p<0,001). Conclusão: percepção dolorosa observada na maioria das mulheres. Os resultados contribuíram para revisão do protocolo institucional para sedação endovenosa e melhor controle álgico.

show abstract

Brachytherapy for cervical cancer: from intracavitary to interstitial technique

Yang,

Ren,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cervical cancer is a common malignant tumor of female reproductive system. Radiation therapy is one of the main methods of cervical cancer treatment, of which brachytherapy is an essential and important part of radiation therapy for locally advanced cervical cancer. With the rapid development of imaging technologies such as computed tomography (CT) and magnetic resonance imaging (MRI), brachytherapy for cervical cancer has gradually developed from traditional two-dimensional image-guided technology to three-dimensional image-guided technology. And there are more and more treatment methods, including intracavitary brachytherapy, interstitial brachytherapy, and intracavitary combined interstitial implantation brachytherapy. We performed a PubMed search for introduce the application progress of intracavity, implantation, intracavity combined implantation brachytherapy and radioactive seed implantation, and discuss the dosimetric feasibility of internal and external fusion irradiation.

show abstract

Five-fraction HDR brachytherapy in locally advanced cervical cancer: A monocentric experience

Cited by 3 publications

References 14 publications

Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario

Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario

Avaliação Da Dor Em Mulheres Com Câncer Cérvico-Uterino Durante a Braquiterapia

Brachytherapy for cervical cancer: from intracavitary to interstitial technique

Contact Info

Product

Resources

About